Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss
Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss
罗氏旗下的吉纳泰克公司获得FDA批准，用于治疗三种主要导致视力丧失的疾病的Vabysmo预填充注射器（PFS）
- Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness –
- Designed to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option –
- Vabysmo PFS will be available for people living with wet AMD, DME and RVO –
- Vabysmo PFS是第一个也是唯一一个使用FDA批准的双特异性抗体治疗可能导致失明的视网膜疾病的预填针筒 -
- 为简化使用而设计，Vabysmo PFS为视网膜专家提供了一个即用型选项 -
- Vabysmo PFS将为患有湿性年龄相关性黄斑变性，糖尿病性黄斑水肿和视网膜静脉阻塞的人提供服务 -